Treatment of Retinopathy of Prematurity by Intravitreal Injection of Bevacizumab

Authors

  • Mohammad Ismail Hossain Professor & Head, Department of Ophthalmology, AFMC, Dhaka
  • Kamrul Hasan Khan Advisor Specialist in Ophthalmology, CMH, Dhaka
  • Jesmin Sultana Advisor Specialist in Paediatrics, CMH, Dhaka
  • Zulfikar Hasan Classified Specialist in Ophthalmology, CMH, Bogura
  • Billal Hossain Classified Specialist in Ophthalmology, CMH, Dhaka
  • Syeed Mehbub Ul Kadir Assistant Professor of Ophthalmology, Sheikh Fazilatunnesa Mujib Eye Hospital and Training Institute, Gopalganj

DOI:

https://doi.org/10.3329/jafmc.v18i2.63990

Keywords:

Retinopathy of prematurity, Intravitreal injection, Bevacizumab

Abstract

Introduction: Retinopathy of prematurity is a vasoproliferative disease of the developing retina that is a significant cause of paediatric morbidity and blindness worldwide. Although management by early treatment ROP (ETROP) criteria has led the way to improving the outcomes of treatment-requiring posterior (zone 1) ROP, the failure rate continues to be significant for aggressive disease. Managing a premature infant with ROP is a significant challenge to ophthalmologists and associated physicians. However, increasingly younger and lower birth-weight infants can survive with advances in neonatal care. 

Objectives: To assess the effectiveness of intravitreal injection of Bevacizumab on regression of retinal neovascularization in stage III, Zone 1, 2 retinopathy of prematurity and aggressive posterior retinopathy of prematurity.

Methods: Intravitreal Injection of Bevacizumab (0.625mg/0.025mL) was performed on 34 eyes of 17 newborns with stage III, Zone 1, 2 retinopathy of prematurity and aggressive posterior retinopathy of prematurity. The changes in retinal neovascularization were assessed by frequent fundoscopy.

Results: Retinopathy of prematurity regressed in all the eyes treated. The retinal vascularization proceeded beyond the demarcation line. Four eyes of 2 patients needed repeat injections. One eye needed an additional laser. There was no injection-related complication observed.

Conclusion: Intravitreal injection of Bevacizumab can be considered an effective modality in treating Retinopathy of Prematurity. It is recommended to perform more studies to assess its long-term effect on the body's vascular system.

JAFMC Bangladesh. Vol 18, No 2 (December) 2022: 24-27

Downloads

Download data is not yet available.
Abstract
6
PDF
3

Downloads

Published

2023-08-21

How to Cite

Hossain, M. I. ., Khan, K. H. ., Sultana, J. ., Hasan, Z. ., Hossain, B. ., & Kadir, S. M. U. . (2023). Treatment of Retinopathy of Prematurity by Intravitreal Injection of Bevacizumab. Journal of Armed Forces Medical College, Bangladesh, 18(2), 24–27. https://doi.org/10.3329/jafmc.v18i2.63990

Issue

Vol. 18 No. 2 (2022)

Section

Original Papers

License

Submission of a manuscript for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted manuscripts become the permanent property of the Journal of Armed Forces Medical College and may not be reproduced by any means in whole or in part without the written consent of the publisher.